Peer-reviewed / Modelling study / People
Embargoed access to the paper and contact details for authors are available in Notes to Editors at the end of the release.
- Most comprehensive study to date finds the burden of nervous system (neurological) conditions is much greater than previously understood, with this diverse group of conditions affecting 43% of the world’s population (3.4 billion individuals) in 2021.
- Neurological conditions were responsible for 443 million years of healthy life lost due to illness, disability, and premature death (disability-adjusted life years) in 2021, making them the top contributor to the global disease burden, ahead of cardiovascular diseases.
- The biggest contributors to neurological health loss globally were stroke, neonatal encephalopathy (brain injury), migraine, Alzheimer’s disease and other dementias, and diabetic neuropathy (nerve damage).
- Collectively, neurodevelopmental and paediatric conditions were estimated to account for almost a fifth of the total neurological burden worldwide, equivalent to 80 million years of healthy life lost in 2021.
- Regions with the highest nervous system burden in 2021 were central and western sub-Saharan Africa, while high-income Asia Pacific and Australasia had the lowest burden.
- The authors warn that the enormous public health impact of these often preventable causes of health loss underscores the urgency for neurological health to be made a global public health priority.
**For regional and individual-level country data, see notes to editors and appendix**
**Infographics available, see notes to editors**
Globally, the number of people living with, or dying from, neurological conditions such as stroke, Alzheimer's disease and other dementias, and meningitis has risen substantially over the past 30 years due to the growth and ageing of the global population as well as increased exposure to environmental, metabolic, and lifestyle risk factors. In 2021, 3.4 billion people experienced a nervous system condition, according to a major new analysis from the Global Burden of Disease, Injuries, and Risk Factors Study (GBD) 2021, published in The Lancet Neurology journal.
The analysis suggests that worldwide, the overall amount of disability, illness, and premature death—a measurement known as disability-adjusted life years (DALYs)—caused by neurological conditions increased by 18% over the past 31 years, rising from around 375 million years of healthy life lost in 1990 to 443 million years in 2021.
The absolute number of DALYs is increasing in large part due to ageing and growing populations worldwide. However, if the impact of demographics is removed through age-standardisation, rates of DALYs and deaths [1] caused by neurological conditions have declined by around a third (27% and 34% respectively) worldwide since 1990—largely due to better awareness, vaccination, and global prevention efforts for some conditions such as tetanus (93% decrease in age-standardised rates of DALYs), meningitis (62% decrease), and stroke (39% decrease).
The top 10 contributors to neurological health loss in 2021 were stroke, neonatal encephalopathy (brain injury), migraine, Alzheimer’s disease and other dementias, diabetic neuropathy (nerve damage), meningitis, epilepsy, neurological complications from preterm birth, autism spectrum disorder, and nervous system cancers. Neurological consequences of COVID-19 (cognitive impairment and Guillain-Barré syndrome) ranked 20th, accounting for 2.48 million years of healthy life lost in 2021 (figure 1).
The most prevalent neurological disorders in 2021 were tension-type headaches (around 2 billion cases) and migraines (about 1.1 billion cases). Diabetic neuropathy is the fastest-growing of all neurological conditions.
“The number of people with diabetic neuropathy has more than tripled globally since 1990, rising to 206 million in 2021,” said co-senior author Dr Liane Ong from the Institute for Health Metrics and Evaluation (IHME), University of Washington, USA. “This is in line with the increase in the global prevalence of diabetes.”
The current study builds on previous GBD analyses [2] to provide the largest and most comprehensive analysis to compare the prevalence and burden (illness and death) of nervous system disorders between countries on a global scale between 1990 and 2021—expanding the number of studied neurological conditions from 15 to 37 that span from birth to later life.
To better reflect that neurological disorders can occur at any stage of life, for the first time the GBD 2021 Nervous System Disorders Collaborators studied neurodevelopmental disorders and neurological conditions in children, and found that they were responsible for almost a fifth (18%) of all DALYs in 2021, accounting for 80 million years of healthy life lost worldwide.
“Every country now has estimates of their neurological burden based on the best available evidence,” said lead author Dr Jaimie Steinmetz from IHME. “As the world’s leading cause of overall disease burden, and with case numbers rising 59% globally since 1990, nervous system conditions must be addressed through effective, culturally acceptable, and affordable prevention, treatment, rehabilitation, and long-term care strategies.”
The study, conducted to inform ongoing advocacy and awareness efforts, will support the WHO’s Intersectoral Global Action Plan on epilepsy and other neurological disorders 2022–2031 (IGAP) that aims to reduce the impact and burden of neurological disorders and improve the quality of life of people with neurological disorders as well as their caregivers and families [3].
Over 80% of neurological deaths and health loss occur in low- and middle-income countries (LMICs)
Overall, estimates reveal striking differences in nervous system burden between world regions and national income levels. In high-income Asia Pacific and Australasia – regions with the best neurological health – the rate of DALYs and deaths were under 3,000 and 65 per 100,000 people, respectively in 2021. In these regions, stroke, migraine, dementia, diabetic neuropathy, and autism spectrum disorders accounted for most health loss (figure 1).
In contrast, in the worst-off regions of western and central sub-Saharan Africa, the rate of DALYs and deaths were up to five times higher (over 7,000 and 198 per 100,000 people respectively) in 2021, with stroke, neonatal encephalopathy (brain injury), dementia, and meningitis the biggest contributors to years of healthy life lost.
“Nervous system health loss disproportionately impacts many of the poorest countries partly due to the higher prevalence of conditions affecting neonates and children under 5, especially birth-related complications and infections,” said Dr Tarun Dua, Unit Head of WHO’s Brain Health unit and one of the co-senior authors of the study. “Improved infant survival has led to an increase in long-term disability, while limited access to treatment and rehabilitation services is contributing to the much higher proportion of deaths in these countries.”
The authors highlight that, as of 2017, only a quarter of countries globally had a separate budget for neurological conditions, and only around half had clinical guidelines. What’s more, the medical personnel who care for people with neurological conditions are unevenly distributed around the world, with high-income countries having 70 times more neurological professionals per 100,000 individuals than LMICs.
Prevention needs to be a top priority
“Because many neurological conditions lack cures, and access to medical care is often limited, understanding modifiable risk factors and the potentially avoidable neurological condition burden is essential to help curb this global health crisis,” said co-lead author Dr Katrin Seeher, Mental Health Specialist at WHO’s Brain Health Unit.
The study quantified the proportion of nervous system burden that was potentially preventable by eliminating known risk factors for stroke, dementia, multiple sclerosis, Parkinson’s disease, encephalitis, meningitis, and intellectual disability.
The analysis suggests that modifying 18 risk factors over a person’s lifetime—most importantly high systolic blood pressure (57% of DALYs)—could prevent 84% of global DALYs from stroke.
Additionally, estimates suggest that controlling lead exposure could reduce the burden of intellectual disability by 63%, while reducing high fasting plasma glucose to normal levels could reduce the burden of dementia by around 15%.
“The worldwide neurological burden is growing very fast and will put even more pressure on health systems in the coming decades,” said co-senior author Dr Valery Feigin, Director of Auckland University’s National Institute for Stroke and Applied Neuroscience in New Zealand. “Yet many current strategies for reducing neurological conditions have low effectiveness or are not sufficiently deployed, as is the case with some of the fastest-growing but largely preventable conditions like diabetic neuropathy and neonatal disorders. For many other conditions, there is no cure, underscoring the importance of greater investment and research into novel interventions and potentially modifiable risk factors.”
“Nervous system conditions include infectious and vector-borne diseases and injuries as well as non-communicable diseases and injuries, demanding different strategies for prevention and treatment throughout life,” said Steinmetz “We hope that our findings can help policymakers more comprehensively understand the impact of neurological conditions on both adults and children to inform more targeted interventions in individual countries, as well as guide ongoing awareness and advocacy efforts around the world.”
Despite these important findings, the authors note several limitations, including that, while they have done their best to capture all nervous system health loss, some conditions were left out because they could not isolate the neurological component, including infections such as HIV, which has a large impact in many parts of the world. And while the study uses the best available evidence, estimates are constrained by the quantity and quality of data, especially in LMICs.
Writing in a linked Comment, Professor Wolfgang Grisold, President of the World Federation of Neurology, London, UK (who was not involved in the study) says, “This important new GBD report highlights that the burden of neurological conditions is greater than previously thought. In the next iteration, more attention should be given to neuromuscular diseases, the effects of cancer in the nervous system, and neuropathic pain. Comparing the disability caused by conditions with episodic occurrence versus those that cause permanent and progressive disease will remain challenging, because the effects on the individuals vary substantially.”
NOTES TO EDITORS
The study was funded by the Bill and Melinda Gates Foundation. The paper was conducted by the GBD 2021 Nervous System Disorders Collaborators and researchers at the University of Washington, Seattle, USA and the World Health Organization, Geneva, Switzerland.
The labels have been added to this press release as part of a project run by the Academy of Medical Sciences seeking to improve the communication of evidence. For more information, please see: http://www.sciencemediacentre.org/wp-content/uploads/2018/01/AMS-press-release-labelling-system-GUIDANCE.pdf if you have any questions or feedback, please contact The Lancet press office pressoffice@lancet.com
Quotes from Authors cannot be found in the text of the Article, but have been supplied for the press release. The Comment quote is taken directly from the linked Comment.
[1] To allow comparisons between countries and over time DALY rates are age-standardised.
[2] Global, regional, and national burden of neurological disorders during 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015 - The Lancet Neurology and Global, regional, and national burden of neurological disorders, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016 - The Lancet Neurology.
[3] Intersectoral global action plan on epilepsy and other neurological disorders (who.int)
Additional key findings include:
- Stroke was the top contributor to age-standardised DALYs in 19 out of 21 GBD regions in 2021—second only to migraine in Western Europe and Australasia (figure 1).
- There were over 23 million global cases of COVID-19 with long-term cognitive symptoms or Guillain−Barre Syndrome in 2021, accounting for over half (57%) of all infectious neurological disease cases, and contributing to 2.48 million years of healthy life lost.
- Diabetic neuropathy (92% increase), neurological complications from neonatal sepsis (70% increase), and cerebral malaria (54% increase), all largely preventable, were the fastest growing causes of age-standardised DALYs over the past three decades, highlighting the poor implementation of effective preventative strategies for these conditions (figure 2).
- In contrast, eight conditions had a 25% or larger decline in age-standardised DALYs: tetanus, rabies, meningitis, neural tube defects, stroke, neurocysticercosis (parasitic infection that affects the central nervous system), encephalitis (inflammation of the brain), and neonatal encephalopathy (brain injury), reflecting improved prevention, care, and research (figure 2).
- Overall, age-standardised DALYs for neurological conditions were lower in females than males globally (5,186 vs 6,101 per 100,000 people)—with neurological consequences of COVID-19, multiple sclerosis, and migraine much higher in females, while age-standardised DALYs from attention deficit hyperactivity disorder (ADHD), traumatic brain injury, and autism spectrum disorder were twice as high in males (figure 2).
Journal
The Lancet Neurology
Method of Research
Computational simulation/modeling
Subject of Research
People
Article Title
Global, regional, and national burden of disorders affecting the nervous system, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021
Article Publication Date
14-Mar-2024
COI Statement
V Aboyans reports consulting fees from Bayer Healthcare, Amarin, Boehringer Ingelheim, and NovoNordisk; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from NovoNordisk and Amarin; and unpaid leadership or fiduciary roles in board, society, committee, or advocacy groups with the European Society of Cardiology and the French Society of Cardiology, all outside the submitted work. S Afzal reports payment or honoraria from educational events and webinars with King Edward Medical University and collaborative partners, including University of Johns Hopkins, University of California, and University of Massachusetts; participation on a data safety monitoring board or advisory board with National Bioethics Committee Pakistan, King Edward Medical University Institutional Ethical Review Board, Ethical Review Board Fatima Jinnah Medical University, and Sir Ganga Ram Hospital; leadership or fiduciary roles in board, society, committee, or advocacy groups, paid or unpaid with Pakistan Association of Medical Editors, the Faculty of Public Health Royal Colleges UK (Fellowship of Faculty of Public Health) as a fellow, the Society of Prevention, Advocacy And Research, King Edward Medical University as a member, and with the Pakistan Society of Infectious Diseases, outside the submitted work. K Akinosoglou reports payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events paid to the University of Patras from Pfizer Hellas, MSD, Gilead, ViiV/GSK, 3M, and Sobi and support for meeting and travel registration and accommodation costs from Pfizer Hellas, MSD, Gilead, Normal Hellas, and LEO Pharmaceuticals Hellas, outside the submitted work. R Ancuceanu reports consulting fees from Abbvie and payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Abbvie, Sandoz, B Braun, and Laropharm, outside the submitted work. P Atorkey reports support for the present manuscript from the Australian College of Applied Professions, Discipline of Psychological Sciences and The University of Newcastle, School of Medicine and Public Health. J Ärnlöv reports payment for lectures, presentations, speakers bureaus, manuscript writing, or educational events from AstraZeneca and Novartis and participation on an advisory board with AstraZeneca, Boerhinger Ingelheim, and Astella, outside the submitted work. R Bai reports support for the present manuscript from the National Natural Science Foundation of China (grant number 72204112), the Social Science Fund of Jiangsu Province (grant number 21GLD008), and the Fundamental Research Funds for the Central Universities (grant number 30923011101). M A Barboza reports payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Pfizer and Roche Pharmaceuticals and support for attending meetings and travel from Boehringer Ingelheim, outside the submitted work. T W Bärnighausen reports grants from the EU (Horizon 2020 and European Institute of Innovation and Technology Health), German Research Foundation, US National Institutes of Health, German Ministry of Education and Research, Alexander von Humboldt Foundation, Else-Kröner-Fresenius-Foundation, Wellcome Trust, Gates Foundation, KfW Development Bank, UNAIDS, and WHO; consulting fees for KfW on the OSCAR Initiative in Viet Nam; participation on a data safety monitoring board or advisory board with NIH-funded study Healthy Options as chair of the data safety and monitoring board, participation on a data safety monitoring board with the German National Committee on the Future of Public Health Research and Education, participation as chair of the scientific advisory board to the European and Developing Countries Clinical Trials Partnership Evaluation, and participation as a member of the UNAIDS Evaluation Expert Advisory Committee, National Institutes of Health Study Section Member on Population and Public Health Approaches to HIV/AIDS, US National Academies of Sciences, Engineering, and Medicine’s Committee for the Evaluation of Human Resources for Health in the Republic of Rwanda under the President’s Emergency Plan for AIDS Relief, and University of Pennsylvania (UPenn) Population Aging Research Center (PARC) External Advisory Board; and leadership or fiduciary roles in board, society, committee or advocacy groups, paid or unpaid with the Global Health Hub Germany as co-chair (which was initiated by the German Ministry of Health), outside the submitted work. S Bhaskar reports grants or contracts from Japan Society for Promotion Science; leadership or fiduciary roles in board, society, committee, or advocacy groups, paid or unpaid with Rotary District 9675 Diversity, Equity and Inclusion as a chair and with Global Health and Migration, Global Health Hub Germany as a founding member, manager, and chair. H Carabin reports grants or contracts from WHO. M Endres reports grants from Bayer (unrestricted grant to Charité for MonDAFIS study and Berlin AFib registry, with no personal fees); consulting fees paid to the institution from Bayer; payment (paid to institution) for honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Bayer, Pfizer, Amgen, GSK, and Novartis; participation on a data safety monitoring board or advisory board (no personal fees) with BMS (country principal investigator for Axiomatic-SSP), Bayer (country principal investigator for NAVIGATE-ESUS), and Daiichi Sankyo; leadership or fiduciary roles in board, society, committee, or advocacy groups, paid or unpaid with the European Academy of Neurology as a member at large on the board of directors and as an unpaid fellow, the German Center for Neurodegenerative Diseases as an unpaid member, the International Society for Cerebral Blood Flow and Metabolism as an unpaid member, the American Health Association and American Stroke Association as an unpaid member, the European Stroke Organisation as an unpaid fellow, the World Stroke Organization as an unpaid member, German Centre of Cardiovascular Research as an unpaid principal investigator, and German Center of Neurodegenerative Diseases as a paid principal investigator under a personal contract; and receipt of equipment, materials, drugs, medical writing, gifts, or other services from Amgen, outside the submitted work. L M Force reports support for the present manuscript from the Gates Foundation; grants or contracts from Conquer Cancer Foundation, St Jude Children’s Research Hospital, St Baldrick’s Foundation, and National Institutes of Health Loan Repayment Program; and leadership or fiduciary roles in board, society, committee, or advocacy groups, unpaid with the Lancet Oncology International Advisory Board. Q Gan reports other financial or nonfinancial interests from the International Agency for Research on Cancer as the beneficiary of the International Agency for Research on Cancer Research and Training Programme. J F Mosser reports grant funding support for the present manuscript for Global Burden of Disease estimation from the Gates Foundation; grants from Gavi, the Vaccine Alliance; and support for attending meetings and travel from the Gates Foundation. S Muthu support for attending meetings and travel from ON Foundation (International Cartilage Regeneration and Joint Preservation Society 2023) and leadership or fiduciary roles in board, society, committee, or advocacy groups, paid or unpaid with the International Society of Orthopaedic Surgery and Traumatology Regeneration and Joint Preservation Society on the NextGEN Committee, outside the submitted work. L Ronfani reports support for the present manuscript from the Italian Ministry of Health (Ricerca Corrente 34/2017), payments made to the Institute for Maternal and Child Health Istituto di Ricovero e Cura a Carattere Scientifico Burlo Garofolo. S Zadey reports honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Think Global Health, Harvard Public Health Magazine, and The Wire Science and leadership or fiduciary roles in board, society, committee, or advocacy groups, paid or unpaid with the Association for Socially Applicable Research as a co-founding director, The G4 Alliance as a permanent council member, Surgical, Obstetric, Trauma and Anesthesia Care in South Asia Working Group as a chair, and Maharashtra State Mental Health Policy as a drafting committee member, outside the submitted work. The authors alone are responsible for the views expressed in this Article, and they do not necessarily represent the views, decisions, or policies of the institutions or funders with which they are affiliated.